We all age and, given the UK's rapidly greying population, the problems associated with age are grabbing headlines as never before. So, when Aricept, the first licensed treatment for Alzheimer's, was launched by Eisai and Pfizer in 1997, demand was expected to be massive. Aricept is effective in the earlier stages of the disease - when sufferers are forgetful rather than totally disorientated - but it offers relief rather than a lasting cure. It works by boosting levels of the chemical acetycholine in the brain, temporarily improving short-term memory and making everyday life a lot easier. A controversial early television advertising campaign caused concern in the medical establishment, particularly about Aricept's cost-effectiveness. A number of health authorities refuse to prescribe it. Sales have been modest but, as one analyst says, 'It's all there is for Alzheimer's.'
The Dexters CEO has seen his company grow despite a challenging market.
Be yourself? It's not quite so simple, says Professor Margarita Mayo.
Private equity boss Andy Grove reveals what investors look for in start-ups.
The Anglo-Dutch giant is now just a Dutch giant, but the UK retains the bulk of corporate jobs.
Both firms faced the same problems, but why has Balfour been able to thrive when Carillion failed?
A letter from Martin Lindstrom to the world's CEOs.